187 related articles for article (PubMed ID: 23200198)
1. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.
Shetty S; Ahmed AR
J Am Acad Dermatol; 2013 Mar; 68(3):499-506. PubMed ID: 23200198
[TBL] [Abstract][Full Text] [Related]
2. Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review.
Farooq MM; Miloslavsky EM; Konikov N; Ahmed AR
Autoimmun Rev; 2022 Aug; 21(8):103119. PubMed ID: 35688385
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for patients with refractory mucous membrane pemphigoid.
Le Roux-Villet C; Prost-Squarcioni C; Alexandre M; Caux F; Pascal F; Doan S; Brette MD; Soued I; Gabison É; Aucouturier F; Letestu R; Laroche L; Bachelez H
Arch Dermatol; 2011 Jul; 147(7):843-9. PubMed ID: 21422323
[TBL] [Abstract][Full Text] [Related]
4. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP).
Maley A; Warren M; Haberman I; Swerlick R; Kharod-Dholakia B; Feldman R
J Am Acad Dermatol; 2016 May; 74(5):835-40. PubMed ID: 26936298
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
[TBL] [Abstract][Full Text] [Related]
7. Rituximab preserves vision in ocular mucous membrane pemphigoid.
Rübsam A; Stefaniak R; Worm M; Pleyer U
Expert Opin Biol Ther; 2015 Jul; 15(7):927-33. PubMed ID: 25966960
[TBL] [Abstract][Full Text] [Related]
8. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
Letko E; Miserocchi E; Daoud YJ; Christen W; Foster CS; Ahmed AR
Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
[TBL] [Abstract][Full Text] [Related]
9. Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab.
Baniel A; Oestreicher-Kedem Y; Peled A; Bar-Ilan E; Geller S; Sprecher E; Baum S
Clin Exp Dermatol; 2021 Jul; 46(5):915-919. PubMed ID: 33811681
[TBL] [Abstract][Full Text] [Related]
10. Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab.
He Y; Shimoda M; Ono Y; Villalobos IB; Mitra A; Konia T; Grando SA; Zone JJ; Maverakis E
JAMA Dermatol; 2015 Jun; 151(6):646-50. PubMed ID: 25901938
[TBL] [Abstract][Full Text] [Related]
11. Treatment of mucous membrane pemphigoid with rituximab.
Heelan K; Walsh S; Shear NH
J Am Acad Dermatol; 2013 Aug; 69(2):310-1. PubMed ID: 23866864
[No Abstract] [Full Text] [Related]
12. Reply to "Treatment of mucous membrane pemphigoid with rituximab".
Ahmed AR; Shetty S
J Am Acad Dermatol; 2013 Aug; 69(2):311-2. PubMed ID: 23866865
[No Abstract] [Full Text] [Related]
13. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
Front Immunol; 2018; 9():248. PubMed ID: 29520266
[TBL] [Abstract][Full Text] [Related]
14. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
Foster CS; Chang PY; Ahmed AR
Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
[TBL] [Abstract][Full Text] [Related]
15. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature.
Shetty S; Ahmed AR
J Drugs Dermatol; 2013 Jun; 12(6):672-7. PubMed ID: 23839185
[TBL] [Abstract][Full Text] [Related]
16. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients.
Lourari S; Herve C; Doffoel-Hantz V; Meyer N; Bulai-Livideanu C; Viraben R; Maza A; Adoue D; Bedane C; Paul C
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1238-40. PubMed ID: 21054575
[No Abstract] [Full Text] [Related]
17. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2013 Nov; 52(11):2041-7. PubMed ID: 23934313
[TBL] [Abstract][Full Text] [Related]
18. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
Li Y; Foshee JB; Sontheimer RD
J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.
Thorne JE; Woreta FA; Jabs DA; Anhalt GJ
Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
